Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pseudolaric Acid B SCHEMBL16426061 | 1.00 | BSG (0.58) | BSGCRBN | |
| Pseudolaric Acid B SCHEMBL29357444 | 1.00 | BSG (0.58) | BSGCRBN | |
| Pseudolaric Acid A SCHEMBL27964349 | 0.88 | BSG (0.47) | BSGCRBN | |
| Pseudolaric Acid A SCHEMBL29785336 | 0.88 | BSG (0.47) | BSGCRBN | |
| Pseudolaric Acid C SCHEMBL28774868 | 0.87 | BSG (0.46) | BSGCRBN | |
| Pseudolaric Acid C SCHEMBL29754805 | 0.87 | BSG (0.46) | BSGCRBN | |
| SCHEMBL28845305 | 0.86 | BSG (0.45) | BSGCRBN | |
| SCHEMBL18561099 | 0.77 | BSG (0.47) | BSGCRBN | |
| SCHEMBL16429224 | 0.74 | BSG (0.37) | BSGCRBN | |
| SCHEMBL8255709 | 0.57 | CHRM3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325717-A1 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-23 | — | — | US | claimed |
| US-20250313647-A1 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-09 | — | — | US | claimed |
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-04-24 | — | — | US | claimed |
| CN-119677779-A | Combination therapy with anti-nucleolin 1 antibodies and antibody conjugates | 儿童医学中心公司 | 2025-03-21 | — | — | CN | claimed |
| EP-4514858-A2 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4514857-A2 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| CN-119487077-A | Mutant and mislocalized cell surface nucleolin 1 as diagnostic and therapeutic targets for human diseases | 儿童医学中心公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119365486-A | EPO receptor agonists and antagonists | 免疫先锋股份有限公司 | 2025-01-24 | — | — | CN | claimed |
| EP-4490187-A2 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | Immunedge, Inc. (US) | 2025-01-15 | — | — | EP | claimed |
| CN-119112876-A | Application of pseudolaric acid B in preparing medicine for preventing or treating non-alcoholic fatty liver disease | 大连医科大学 | 2024-12-13 | — | — | CN | claimed |
| CN-115869244-A | Anti-inflammatory and nursing liposome temperature-sensitive gel for vagina and preparation method thereof | 广州金天芳颜化妆品有限公司 | 2023-03-31 | — | — | CN | claimed |
| US-20230012268-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) | 2023-01-12 | — | — | US | claimed |
| CN-115252602-A | Application of pseudolaric acid B in pharmacodynamic research of antitumor drugs | 吉林大学 | 2022-11-01 | — | — | CN | claimed |
| EP-4072558-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR | Buzzelet Development And Technologies Ltd (IL) | 2022-10-19 | — | — | EP | claimed |
| CN-114794116-A | Pesticide composition containing pseudolaric acid B and application thereof in preventing and treating plant diseases | 兰州大学 | 2022-07-29 | — | — | CN | claimed |
| CN-113244225-B | Application of pseudolaric acid B in preparation of antiplatelet drugs | 昆明医科大学第一附属医院 | 2022-06-28 | — | — | CN | claimed |
| CN-114668757-A | Application of pseudolaric acid B in preparing medicine for preventing and/or treating malignant tumor | 葛鹏飞 | 2022-06-28 | — | — | CN | claimed |
| CN-113133964-B | Multifunctional nail polish and preparation method thereof | 浙江珍珠生活科技有限公司 | 2022-06-14 | — | — | CN | claimed |
| WO-2022056021-A1 | METHODS OF DETECTING AN INACTIVATING MUTATION OF PBRM1 IN MENINGIOMA | FOUNDATION MEDICINE, INC. (US) | 2022-03-17 | — | — | WO | claimed |
| CN-113995749-A | Application of pseudolaric acid B in preparing medicine for treating pulmonary hypertension | 大连医科大学 | 2022-02-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, MPL, PRLHR | BSG 1131/4885CRBN 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.